BRAF and central nervous system cancer: The combined BRAF/MEK-inhibitor therapy was first implemented in BRAFV600E-mutant, malignant melanoma (MM), but several groups also reported on patients with BRAFV600E–mutant gliomas or eGB who have responded to MAPKi [11–16].